Skip to main content
Clinical Trials/NL-OMON28081
NL-OMON28081RecruitingNot Applicable

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC Cancer Institute, Clinical Trial CenterP.O. Box 20403000 CA RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl0 sites260 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
260

Study Overview

Brief Summary

ot yet for this trial.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • First diagnosis of high risk Burkitt lymphoma (sporadic and
  • HIV associated), histologically confirmed according to the
  • WHO classification 2008. Upon its availability the WHO 2016
  • classification should be used, to replace the WHO 2008
  • classification;

Exclusion Criteria

  • - All histopathological diagnoses other than Burkitt
  • lymphoma according to the WHO classification 2008,
  • irrespective of the presence of a MYC rearrangement. Upon
  • its availability the WHO 2016 classification should be used, to
  • replace the WHO 2008 classification;

Investigators

Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC Cancer Institute, Clinical Trial CenterP.O. Box 20403000 CA RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl

Similar Trials